Mackenzie Financial
GILD icon

Mackenzie Financial’s Gilead Sciences GILD Stock Holding History

Mackenzie Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,600
Closed -$3.42K – 1756
2025
Q2 		$3.42K Buy
+12,600
New +$1.34M ﹤0.01% 1696

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Mackenzie Financial's GILD Position: Q1 2026 in Review

Mackenzie Financial reduced its Gilead Sciences (GILD) stake by 43% in Q1 2026, selling an estimated $107M and leaving 1,017,219 shares worth $142M. The position accounts for 0.17% of the portfolio, ranked #119.

Mackenzie Financial first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $280M in Q2 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Mackenzie Financial held 1,017,219 shares of Gilead Sciences worth $142M as of Q1 2026.
  • Mackenzie Financial sold 761,326 Gilead Sciences shares in Q1 2026, an estimated $107M.
  • Gilead Sciences made up 0.17% of Mackenzie Financial's portfolio in Q1 2026, its #119 holding.
  • Mackenzie Financial first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Mackenzie Financial's Gilead Sciences position peaked at $280M in Q2 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.